Sarepta Therapeutics Inc (SRPT) Company Profile & Statistics

Sarepta Therapeutics Inc
SRPT
(Nasdaq - US)
Closed
110.50
-0.36 (-0.33%)
in:usd•As of: Nov 21, 2024 15:59 UTC -5
After Market:111.1+0.60 (+0.54%)
Open
111.78
High
111.78
Low
109.02

About Sarepta Therapeutics Inc

CEO

Douglas S. Ingram

Headquarters

215 first street, suite 415

cambridge, ma 02142, united states

Auditor

KPMG LLP

Employees

1,314

Share Holders

157

Website

www.sarepta.com

Industry

pharmaceuticals major

Sector

health technology

Company Overview

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company that focuses on the discovery and development of RNA-based therapeutics targeting rare and infectious diseases. It concentrates on the development of exon-skipping drug candidates targeting Duchenne muscular dystrophy (DMD), a rare genetic disorder affecting children. The company received accelerated approval for Exondys 51, Amondys 45 (casimersen) and Vyondys 53 (golodirsen). Exondys 51 is Sarepta's first PMO-based technology to be granted accelerated approval by the FDA. The company is conducting a confirmatory study on the clinical benefits of these drugs for gaining continued approval. The rest of its exon-skipping DMD pipeline includes a PPMO-based, exon 51 skipping candidate, SRP-5051. Sarepta is also developing gene therapies for treating DMD, Limb-girdle muscular dystrophy and central nervous system disorders including Mucopolysaccharidosis type IIIA and Pompe Disease.

Sarepta Therapeutics Inc Statistics

Valuation Measures

Market Capitalization ²	10.55B
Enterprise Value	11.58B
Enterprise Value/EBITDA (ttm)	158.99
Price to Earnings Ratio (ttm)	91.91
Price to Book (mrq)	8.33
Price to Sales (ttm)	6.21
Price to Cash (ytd)	N/A

Profitability

Gross Margin (ttm)	86.18%
Operating Margin (ttm)	6.90%
Profit Margin (ttm)	7.30%
Return on Equity (ttm)	11.00%
Return on Invested Capital (ttm)	5.73%
Return on Assets (ttm)	3.35%

Income Statement

Revenue (ttm)	1.64B
Revenue Per Share (ttm)	17.17
Gross Profit (ttm)	1.41B
EBITDA (ttm)³	72.86M
Net Income Avi to Common (ttm)	121.84M
Diluted EPS (ttm)	1.25

Share Statistics

Beta (5Y Monthly)	0.81
52-Week Change	33.04%
S&P500 52-Week Change	30.55%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	95.52M
Dividend Yield	0.00%
Float ⁴	88.17M
% Held by Insiders	7.70%
% Held by Institutions	86.68%

Balance Sheet

Total Cash (mrq)	1.20B
Total Cash Per Share (mrq)	12.55
Total Debt (mrq)	1.23B
Total Debt/Equity (mrq)	100.53%
Current Ratio (mrq)	3.84%
Quick Ratio (mrq)	3.03%
Book Value Per Share (mrq)	12.79

Cash Flow

Operating Cash Flow Per Share (ytd)	-2.96
Free Cash Flow (ytd)	-396.71M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Sarepta Therapeutics Inc

Trade With A Regulated Broker